These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 21627375

  • 1. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
    Li Y, Huang XE, Jin GF, Shen HB, Xu L.
    Asian Pac J Cancer Prev; 2011; 12(3):739-42. PubMed ID: 21627375
    [Abstract] [Full Text] [Related]

  • 2. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, Pan LX, Tang JH.
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [Abstract] [Full Text] [Related]

  • 3. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R, Spanish Lung Cancer Group.
    Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
    [Abstract] [Full Text] [Related]

  • 4. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y, Wang D.
    Int J Cancer; 2014 Dec 01; 135(11):2687-96. PubMed ID: 24729390
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Tarón M, Berrocal A, Blasco S, Caballero C, Del Pozo N, Rosell R, Camps C.
    Clin Lung Cancer; 2011 Jul 01; 12(4):224-30. PubMed ID: 21726821
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH, Deng J, Shi DH, Ouyang XN, Niu PG.
    Clin Transl Oncol; 2015 Sep 01; 17(9):720-6. PubMed ID: 26033426
    [Abstract] [Full Text] [Related]

  • 7. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
    Li XD, Han JC, Zhang YJ, Li HB, Wu XY.
    Asian Pac J Cancer Prev; 2013 Sep 01; 14(1):145-8. PubMed ID: 23534713
    [Abstract] [Full Text] [Related]

  • 8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R, Krawczyk P, Homa-Mlak I, Powrózek T, Ciesielka M, Kozioł P, Milanowski J, Małecka-Massalska T.
    Pathol Oncol Res; 2019 Jul 01; 25(3):1035-1045. PubMed ID: 30066234
    [Abstract] [Full Text] [Related]

  • 9. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P, Wang YD, Cheng J, Chen JC, Ha MW.
    Tumour Biol; 2015 Dec 01; 36(12):9465-73. PubMed ID: 26124006
    [Abstract] [Full Text] [Related]

  • 10. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.
    Clin Lung Cancer; 2013 Jul 01; 14(4):433-9. PubMed ID: 23522953
    [Abstract] [Full Text] [Related]

  • 11. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
    Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, Lu Z, Chen B.
    Technol Cancer Res Treat; 2013 Oct 01; 12(5):473-82. PubMed ID: 23617284
    [Abstract] [Full Text] [Related]

  • 12. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R.
    Clin Cancer Res; 2008 Mar 15; 14(6):1797-803. PubMed ID: 18347182
    [Abstract] [Full Text] [Related]

  • 13. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, Zhong R, Xu Y, Wu J, Yu D, Wu T, Zhang X, Nie S, Miao X, Lin D.
    Lung Cancer; 2011 Jul 15; 73(1):110-5. PubMed ID: 21129812
    [Abstract] [Full Text] [Related]

  • 14. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.
    Clin Lung Cancer; 2009 Mar 15; 10(2):118-23. PubMed ID: 19362955
    [Abstract] [Full Text] [Related]

  • 15. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population.
    Du Y, He Y, Mei Z, Qian L, Shi J, Jie Z.
    Clin Respir J; 2016 May 15; 10(3):311-7. PubMed ID: 25308691
    [Abstract] [Full Text] [Related]

  • 16. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Sun Y, Zhang XR, Xu BH, Lin DX.
    Zhonghua Zhong Liu Za Zhi; 2006 Mar 15; 28(3):196-9. PubMed ID: 16875604
    [Abstract] [Full Text] [Related]

  • 17. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC.
    J Clin Oncol; 2004 Jul 01; 22(13):2594-601. PubMed ID: 15173214
    [Abstract] [Full Text] [Related]

  • 18. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ.
    Asian Pac J Cancer Prev; 2012 Jul 01; 13(5):2157-62. PubMed ID: 22901187
    [Abstract] [Full Text] [Related]

  • 19. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY, Zheng Y, Wang Y, Chen J, Liu JY, Zhou HH, Yin JY, Liu ZQ.
    Chin J Cancer; 2016 Sep 02; 35(1):85. PubMed ID: 27590272
    [Abstract] [Full Text] [Related]

  • 20. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
    Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, Kim CS, Kim HJ, Lee JE.
    J Thorac Oncol; 2011 Aug 02; 6(8):1320-9. PubMed ID: 21642870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.